Introduction
Tuberculosis (TB) is a main health problem in developing and developed countries [1] . The WHO showed 8.6 billion new cases of TB worldwide in 2012 and 1.3 million deaths [2] . Latent tuberculosis (LTBI) is defined as infection with Mycobacterium tuberculosis, but there is no active TB disease. Overall, 10-15 billion people in USA have LTBI. Owing to the fact that 5-10% of people with LTBI are subjected to development of active disease, recognition and management of LTBI are mandatory. Screening is required for high-risk population. Tuberculin testing is the best way for LTBI identification. Other new tests include interferon-γ (IFN-γ) release assays. The treatment of choice for LTBI is isoniazid for 9 months. Liver cell injury is the most alarming adverse effect. Isoniazide (INH) should be stopped if liver enzymes are elevated more than three-folds of the normal value in symptomatic patients or five-folds of the normal value in asymptomatic patients [3] .
Virus C is a considerable cause of liver diseases, including chronic hepatitis, cirrhosis, and hepatocellular carcinoma [4] . Hepatitis C virus (HCV) strains are divided into six genotypes (1) (2) (3) (4) (5) (6) , each including many subgroups (named a, b, c, etc.) [5, 6] . A seventh genotype (subtype 7a) was recently discovered [7] . More than 200 billion people are
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infected with hepatitis C, with an estimated HCV prevalence of 2.2% worldwide. HCV is responsible for 27% of cirrhosis cases and 25% of hepatocellular carcinoma cases globally. Egypt has the highest prevalence of hepatitis C (10=15%) [8, 9] . HCV is characterized by a high degree of genetic heterogeneity [10] .
Aim
The aim was to study the prevalence of LTBI among people infected with HCV for preventing emergence of active TB disease during treatment of HCV with antiviral drugs that cause immunosuppression.
Patients and methods
This study was carried on 75 patients who were divided into two groups: group A (hepatitis C group), which had 45 patients, and group B (control group), which had 30 patients. A written consent was taken from patients who participated in the study. Patients underwent the following:
(1) History taking. 
Tuberculin skin test:
The tuberculin skin test (TST) is the method of LTBI screening. Overall, 0.1 ml (5 tuberculin units) of PDD (purified protein derivatives) is injected intradermally in the anterior surface of the forearm, commonly the anterior surface. This causes a raised induration of 6-10 mm in diameter. The induration is seen after 48-72 h and remains positive for 1 week [11] . If the test was negative after 72 h, it should be repeated, because of the booster phenomenon. Test interpretation is by measurement of induration not erythema. The Centers for Disease Control and Prevention has announced protocols for reading of the TST [12] . The TST is a delayed hypersensitivity reaction which become positive 2-12 weeks after infection with M. tuberculosis. Reaction positivity depend on the health status and TB infection risk of the patient (Table 1) [11, 13] . In higher risk groups, a small reaction size is required to increase test sensitivity [14] .
Interferon-γ release assays
INF-γ release assay are postulated to reveal the immune reaction to specific mycobacterial TB antigens, which are absent in BCG or certain non-TB mycobacteria. Two types are present in the market: the first is based on the Elispot (T-SPOT. TB; Oxford Immunotec, UK) and the second on the enzyme-linked immunosorbent assays technique (QuantiFERON TB Gold-in-Tube, QFT-GIT; Cellestis, Carnegie, Victoria, Australia). The principle of the two tests is based on that the T lymphocytes of a person who are infected with TB will respond by elaborating the cytokine IFN-γ when stimulated second time with mycobacterial TB antigens. For avoidance of crossreactivity, the tests use antigens whose code is present in the region of difference 1, a part of the mycobacterial TB genome that is not present in the genome of BCG and most atypical mycobacteria. The QFT-GIT makes use of the whole blood of the patient, and its base is to measure the enzyme-linked immunosorbent assays of IFN-γ produced in response to three mycobacterial TB antigens (ESAT-6, CFP-10, and TB7.7). The other test, T-SPOT. TB, is based on the enzyme-linked immunospot measurement of the number of peripheral mononuclear cells that produce IFN-γ after stimulation with two mycobacterial antigens: ESAT-6 and CFP-10 [15] .
Results
This study was carried on 75 patients who were divided into two groups: group A (hepatitis C group), which included 45 patients, and group B (control group), which included 30 patients (Figs 1-4 ).
Discussion
TB remains oneof the 'Captain of the Men of Death' to this day, especially in the developing world. It is 14 times more frequent in patients with chronic liver disease and cirrhosis, and more common in people with decompensated disease, probably owing to the cirrhosis-associated immune dysfunction, and casefatality rates are high. The diagnosis of TB, particularly the interpretation of the Mantoux test, is also fraught with difficulties in chronic liver disease, especially after previous BCG vaccination [16] .
The aim of the work is to study the prevalence of LTBI among patients with HCV infection to prevent development of active TB disease during treatment of HCV with antiviral drugs that cause immunosuppression.
This study was carried on 75 patients who were divided into two groups: group A (hepatitis C group), which comprised 45 patients, and group B (control group), which had 30 patients. Tables 2 and 3 show the demographic data of the studied groups. Table 2 shows age distribution among the studied group with mean age of 54.9±10.23 years in group A (hepatitis C group) and 61.1±9.2 years in group B (control group). There is no significant difference between the two groups regarding the age. Table 3 shows sex distribution among the studied groups. In group A, there are 30 (66.7%) males and Sex distribution among the studied groups.
Figure 2
Tuberculin test distribution among the studied groups.
Figure 4
Radiographic finding distribution among the studied groups.
Figure 3
QuantiFERON tuberculosis gold test distribution among the studied groups.
15 (33.3%) females, whereas in group B, there are 16 (53.3%) males and 14 (46.7%) females, with no significant difference between the two groups.
In their study, Uehara et al. [17] found that most patients were male (78%), with a mean age of 49±10 years.
Egypt has the highest HCV prevalence in the world, where the prevalence increases steadily with age, and high rates of infection are observed among persons in all age groups [18] . A large number of patients are detected to have LTBI by tuberculin testing, and most patients have asymptomatic TB, which is not apparent clinically. The interpretation of a Mantoux test is difficult in patients with liver cirrhosis, as most patients have deficiencies in their immune function [19] .
Tuberculin reactivity has been documented in 20-25% of these patients, although a vast majority of transplant candidates are anergic [20] .
Tuberculin test can identify a subgroup at risk for developing TB after transplantation [21, 22] . Multiple studies have compared QuantiFERON TB gold test with the TST in the general population, children, healthcare workers, and in countries with a high incidence of TB [23] [24] [25] [26] . However, few studies have compared both tests in immunocompromised patients [27, 28] .
This result coincides with the results of Trajman et al. [29] who found that QuantiFERON TB gold test has high sensitivity (78%) and specificity (98%) over the TST.
IFN-γ release assay is an alternative to PPD testing. The test requires only a single contact with a patient. In addition, unlike the PPD, which is subject to interpretation bias, IFN-γ release assays are machine read and have single cutoffs. Thus, there is little subjectivity to the reading of results. IFN-γ release assays have been tested and found to perform reasonably well in healthy populations [22, 23, 30] . Discordance between TST and QFT-G in terms of diagnosing LTBI has been reported in countries with a low, intermediate, and high TB burden [31] [32] [33] .
The use of interferon (IFN-c) release assays in this high-risk group has the advantage of being less affected by energy and not subject to cross-reactions in BCGvaccinated individuals. This enables a better targeting of this high-risk group for the treatment of LTBI [34] . Kang et al. [32] reported that the IFN-γ assay is a better indicator of the risk of M. tuberculosis infection than TST.
In a recent study from Mumbai, Baijal et al. [35] found that the prevalence of TB in patients with liver cirrhosis was fifteen times higher than in the general population and was significantly higher in alcoholics. However, Wu et al. [36] found that patients with liver cirrhosis did not have an increased risk of pulmonary TB. Table 6 shows radiographic finding distribution among the studied groups. In group A there are nine (20%) patients with positive radiographic findings and 36 (80%) patients with negative findings, whereas in group B, there are only two (6.7%) patients with positive radiographic findings and 28 (93.3%) patients with negative findings. There is no significant difference between the two groups regarding radiographic findings.
Summary and conclusion
Patients with HCV infection should undergo testing for LTBI to prevent development of active TB disease during treatment of HCV with antiviral drugs that cause immunosuppression. QuantiFERON TB Gold test is better than TST in detecting LTBI in patient with hepatitis C because tuberculin test may be falsely negative in patient with immunosuppression and patients with hepatic disorders, which may give unreliable results.
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